Survivin-specific T cell receptor targets tumor but not T cells

Journal of Clinical Investigation

Volumn 125, Issue 1, 2015, Pages 157-168

  Arber, Caroline ^a,b   Feng, Xiang ^b   Abhyankar, Harshal ^a   Romero, Errika ^a   Wu, Meng Fen ^c   Heslop, Helen E ^a,b   Barth, Patrick ^b,d,e   Dotti, Gianpietro ^a,b,f   Savoldo, Barbara ^a,b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b Department of Medicine ^*  (United States)

^c Dan L Duncan Cancer Center   (United States)

^d Verna and Marrs McLean Department of Biochemistry and Molecular Biology   (United States)

^e Graduate Program of Structural and Computational Biology and Molecular Biophysics   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; SURVIVIN; SURVIVIN SPECIFIC T CELL RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL ENGINEERING; COLONY FORMING UNIT; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MODEL; MOLECULAR RECOGNITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; CANCER TRANSPLANTATION; COCULTURE; CYTOTOXIC T LYMPHOCYTE; HL 60 CELL LINE; IMMUNOLOGY; IMMUNOTHERAPY; K562 CELL LINE; LEUKEMIA; PHYSIOLOGY; TRANSPLANTATION;

ANIMALS; COCULTURE TECHNIQUES; CROSS REACTIONS; HL-60 CELLS; HUMANS; IMMUNOTHERAPY; INHIBITOR OF APOPTOSIS PROTEINS; K562 CELLS; LEUKEMIA; MICE; NEOPLASM TRANSPLANTATION; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84920390437     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI75876     Document Type: Article

References (34)

1. Morgan RA, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-129.
2. Johnson LA, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535-546.
3. Robbins PF, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917-924.
4. Cheever MA, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323-5337.
5. Rapoport AP, et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood. 2011;117(3):788-797.
6. Becker JC, et al. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in met-astatic melanoma. Cancer Immunol Immunother. 2012;61(11):2091-2103.
7. Leisegang M, et al. MHC-restricted fratricide of human lymphocytes expressing survivin-spe-cific transgenic T cell receptors. J Clin Invest. 2010;120(11):3869-3877.
8. Spranger S, et al. TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo. Blood. 2012;119(15):3440-3449.
9. Li Y, et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol. 2005;23(3):349-354.
10. Cameron BJ, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5(197):197ra103.
11. Linette GP, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863-871.
12. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cyto-toxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001;61(16):5964-5968.
13. Qian B, et al. High-resolution structure prediction and the crystallographic phase problem. Nature. 2007;450(7167):259-264.
14. Raveh B, London N, Schueler-Furman O. Sub-angstrom modeling of complexes between flexible peptides and globular proteins. Proteins. 2010;78(9):2029-2040.
15. Chaudhury S, Berrondo M, Weitzner BD, Muthu P, Bergman H, Gray JJ. Benchmarking and analysis of protein docking performance in Rosetta v3.2. PLoS One. 2011;6(8):e22477.
16. Wilde S, et al. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood. 2009;114(10):2131-2139.
17. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3(1):46-54.
18. Wohlschlaeger J, et al. Cardiomyocyte survivin protein expression is associated with cell size and DNA content in the failing human heart and is reversibly regulated after ventricular unloading. J Heart Lung Transplant. 2010;29(11):1286-1292.
19. Levkau B. Survivin signalling in the heart. J Mol Cell Cardiol. 2011;50(1):6-8.
20. Xing Z, Conway EM, Kang C, Winoto A. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeo-stasis. J Exp Med. 2004;199(1):69-80.
21. Kornacker M, Verneris MR, Kornacker B, Schef-fold C, Negrin RS. Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol Lett. 2001;76(3):169-173.
22. Tynan FE, et al. T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide. Nat Immunol. 2005;6(11):1114-1122.
23. Birnbaum ME, et al. Deconstructing the peptide-MHC specificity of T cell recognition. Cell. 2014;157(5):1073-1087.
24. Huseby ES, Crawford F, White J, Kappler J, Mar-rack P. Negative selection imparts peptide specificity to the mature T cell repertoire. Proc Natl Acad Sci U S A. 2003;100(20):11565-11570.
25. Huseby ES, Crawford F, White J, Marrack P, Kappler JW. Interface-disrupting amino acids establish specificity between T cell receptors and complexes of major histocompatibility complex and peptide. Nat Immunol. 2006;7(11):1191-1199.
26. Hoyos V, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010;24(6):1160-1170.
27. Quintarelli C, et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood. 2008;112(5):1876-1885.
28. Leen AM, et al. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-spe-cific cytotoxic T lymphocytes for therapeutic applications. Blood. 2004;103(3):1011-1019.
29. Perna SK, et al. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res. 2013;19(1):106-117.
30. Quintarelli C, et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007;110(8):2793-2802.
31. London N, Raveh B, Cohen E, Fathi G, Schuel-er-Furman O. Rosetta FlexPepDock web server - high resolution modeling of peptide-protein interactions. Nucleic Acids Res. 2011;39(Web Server issue):W249-W253.
32. Soding J, Biegert A, Lupas AN. The HHpred interactive server for protein homology detection and structure prediction. Nucleic Acids Res. 2005;33(Web Server issue):W244-W248.
33. Barth P, Wallner B, Baker D. Prediction of membrane protein structures with complex topologies using limited constraints. Proc Natl Acad Sci U S A. 2009;106(5):1409-1414.
34. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol. 2006;24:419-466.